Slides From Peter McCullough, MD Oct 1, 2021 Lecture

Winning the War Against
Therapeutic Nihilism and the Rush to

Replace Trusted Treatments with
Untested Novel Therapies
Peter A. McCullough, MD, MPH, FACC, FAHA, FASN, FNKF, FNLA, FCRSA
Chief Medical Advisor, Truth for Health Foundation
President, Cardiorenal Society of America
Editor-in-Chief, Reviews in Cardiovascular Medicine
Senior Associate Editor, American Journal of Cardiology
Tagline: https://americaoutloud.com/the-mccullough-report/
Dr. McCullough is an internist, cardiologist, epidemiologist. He maintains ABIM certification in internal medicine and cardiovascular
diseases. He practices both internal medicine including the management of common infectious diseases as well as the cardiovascular
complications of both the viral infection and the injuries developing after the COVID-19 vaccine in Dallas TX, USA. Since the outset of the
pandemic, Dr. McCullough has been a leader in the medical response to the COVID-19 disaster and has published “Pathophysiological
Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection” the first synthesis of sequenced multidrug
treatment of ambulatory patients infected with SARS-CoV-2 in the American Journal of Medicine and subsequently updated in Reviews in
Cardiovascular Medicine. He has 46 peer-reviewed publications on the infection and has commented extensively on the medical
response to the COVID-19 crisis in TheHill and on FOX NEWS Channel. On November 19, 2020, Dr. McCullough testified in the US
Senate Committee on Homeland Security and Governmental Affairs and throughout 2021 in the Texas Senate Committee on Health and
Human Services, Colorado General Assembly, New Hampshire Senate, and South Carolina Senate concerning many aspects of the
pandemic response. Dr. McCullough has had one full-year of dedicated academic and clinical efforts in combating the SARS-CoV-2 virus
and in doing so, has reviewed thousands of reports, participated in scientific congresses, group discussions, press releases, and has been
considered among the world's experts on COVID-19.
After months of negative media coverage, the Guillain-Barre reports brought an overdue end to the swine flu
affair. Ford’s programme was suspended in December 1976 with only some 20% of the US population (55M)
vaccinated leaving 550 cases of Guillain-Barre and 25 deaths And since the US government had offered
liability coverage to the pharmaceutical manufacturers that summer, hundreds of compensation
claims from Guillain-Barre claimants followed for years afterward.
Outline
•New biological products
•COVID-19 Vaccine Safety Review
•Failure of COVID-19 Vaccines to Stop
SARS-CoV-2
•Pivot to Early Therapy for High-Risk COVID-19
•Freedom At Risk
•Censorship of Scientific Discourse
•Conclusions
Outline
SARS-CoV-2
•Freedom At Risk
•Conclusions
Clinical Concerns
-mRNA or adenoviral DNA induce production of the Spike protein
-Cell, tissue, organ endothelial damage
-Spike protein circulation (body fluids, donated blood)
-No genotoxicity, teratogenicity, or oncogenicity studies
-Concerning ovarian biodistribution study (Pfizer, Japan)
-Concerning reduced fertility study (Moderna, EMA)
-No EAC, DSMB, Human Ethics Committee
-No restriction of properly excluded groups from RCTs
-Pregnant women, women of childbearing potential
-COVID survivors, previously immune
-No effort to restrict vaccination according to risk for COVID-19
hospitalization and death
-No attempts to present or mitigate risks for public
Outline
SARS-CoV-2
•Freedom At Risk
•Conclusions
Emerging COVID-19 Vaccine
Mortality Signal by Jan 22, 2021
(~27.1 M)
All vaccines before 2020
~158 total deaths/yr
Historical PreCOVID ~280M Injections/year:
All ~70 vaccines average expected 16,320 VAERS total reports/yr, ~158 total deaths/yr
Day of Death after
COVID-19 Vaccination
86% of deaths had no other
explanation than the vaccine
Mclachlan, Scott & Osman, Magda & Dube, Kudakwashe & Chiketero, Patience & Choi, Yvonne & Fenton,
Norman. (2021). Analysis of COVID-19 vaccine death reports from the Vaccine Adverse Events Reporting
System (VAERS) Database Interim Results and Analysis. 10.13140/RG.2.2.26987.26402.
Mclachlan, Scott & Osman, Magda & Dube, Kudakwashe & Chiketero, Patience & Choi, Yvonne & Fenton, Norman. (2021). Analysis of COVID-19 vaccine death
reports from the Vaccine Adverse Events Reporting System (VAERS) Database Interim Results and Analysis. 10.13140/RG.2.2.26987.26402.
https://www.researchgate.net/publication/352837543_Analysis_of_COVID-19_vaccine_death_reports_from_the_Vaccine_Adverse_Events_Reporting_System_VAERS
_Database_Interim_Results_and_Analysis
Outline
SARS-CoV-2
•Freedom At Risk
•Conclusions
Failure of Pfizer-BNT Vaccine in Israel
https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html
23% of Americans
Hospitalized with COVID-19
have been vaccinated
Indiscriminate Vaccination is Reducing the Diversity of
Strains and Producing Dominant Variants
Delta Viral Load in Vaccinated and Unvaccinated Individuals
Outline
SARS-CoV-2
•Freedom At Risk
•Conclusions
Why might an approved drug be used for an
unapproved use?
From the FDA perspective, once the FDA approves a drug,
healthcare providers generally may prescribe the drug for an
unapproved use when they judge that it is medically appropriate
for their patient. You may be asking yourself why your healthcare
provider would want to prescribe a drug to treat a disease or
medical condition that the drug is not approved for. One reason is
that there might not be an approved drug to treat your disease or
medical condition. Another is that you may have tried all
approved treatments without seeing any benefits. In situations
like these, you and your healthcare provider may talk about using
an approved drug for an unapproved use to treat your disease or
medical condition.
https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label
N=849 PCR + High Risk COVID-19
Procter BC, Ross C, Pickard V, Smith E, Hanson C, McCullough PA. Clinical outcomes after early ambulatory
multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Rev Cardiovasc Med. 2020 Dec
30;21(4):611-614. doi: 10.31083/j.rcm.2020.04.260. PMID: 33388006.
Outline
SARS-CoV-2
•Freedom At Risk
•Conclusions
Medical Freedom
Social Freedom
Economic Freedom
Outline
SARS-CoV-2
•Freedom At Risk
•Conclusions
Outline
SARS-CoV-2
•Freedom At Risk
•Conclusions
Conclusions
• COVID-19 pandemic is a global disaster
• Pathophysiology is complex—not amenable to single drug
• The prehospital phase is the time of therapeutic opportunity
• Hospitalization and late treatment form an inadequate safety net with
unacceptably high mortality
• Early ambulatory therapy with a sequenced, multi-drug regimen is
supported by available sources of evidence and has a positive benefit-to-risk
profile
• Reduce the risk of hospitalization and death
• More safely temporize to close the crisis with vaccination and natural herd immunity
• COVID-19 genetic vaccines have an unfavorable safety profile and are not
sufficiently effective, thus they cannot be generally supported in clinical
practice at this time
• Censorship and reprisal are working to crush freedom of speech, scientific
discourse, and medical progress

Slides From Peter McCullough, MD Oct 1, 2021 Lecture

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Slides From Peter McCullough, MD Oct 1, 2021 Lecture

Uploaded by

Copyright:

Available Formats

Winning the War Against

Therapeutic Nihilism and the Rush to

You might also like